elacridar has been researched along with Kidney Neoplasms in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arano, Y; Gushimiyagi, K; Kashiba, T; Nomura, Y; Sato, H; Sekine, Y; Siddig, S; Suzuki, S; Uehara, T; Ueno, K; Uzu, M; Yamaura, K | 1 |
1 other study(ies) available for elacridar and Kidney Neoplasms
| Article | Year |
|---|---|
Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells.
Topics: Acridines; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Survival; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Indoles; Kidney Neoplasms; Kinetics; Membrane Transport Modulators; Neoplasm Proteins; Protein Kinase Inhibitors; Pyrroles; RNA, Messenger; Sunitinib; Tetrahydroisoquinolines | 2015 |